A.A. Samusieva
Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine



 Summary. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with poor prognosis, lacks of standard biomarkers and tumor heterogeneity. So it is the lack of therapeutic biomarkers and tumor heterogeneity are the main causes of therapeutic resistance in the case of TNBC. Differences in tumor cell properties are provides by enzymes that are important potential therapeutic targets. This is makes the exploring of prognostic biomarkers and potential therapeutic targets of TNBC an important area of research. Aim: to improve treatment outcomes for patients with TNBC by evaluating topoisomerase 2 alpha as a potential predictive marker of treatment efficacy. Objects and methods: the study involved 45 patients with II-III stages of TNBC. In addition to standard biomarkers, the level of topoisomerase II alpha expression was determined by the immunohistochemistry. Instrumental methods of diagnosis, pathomorphological and immunohistochemistry, as well as statistical methods of evaluating the obtained data were used in the study. Results: the taxane-containing chemotherapy regimens in patients with TNBC increases the response to treatment. Topoisomerase II alpha overexpression is associated with better prognosis and response to treatment in patients with TNBC. Conclusions: the main results of study allow us to consider topoisomerase II alpha as a prognostically valuable marker for predicting the course of the disease and the response to chemotherapy, as well as the advantage of taxane-containing treatment regimens in patients with TNBC.

Keywords: triple-negative breast cancer, topoisomerase II alpha (ТОР ІІα), taxanes, pathological response, molecular markers.



  1. Cancer today [Internet]. [cited 2023 Apr 18]. Available from:
  2. SEER*Explorer Application [Internet]. [cited 2023 Apr 24]. Available from: https://seer.cancgov/statistics-network/explorer/application.html?site=55&data_type=1&graph_type=2&compareBy=subtype&chk_subtype_622=622&chk_subtype_623=623&chk_subtype_620=620&chk_subtype_621=621&hdn_rate_type=1&sex=3&race=1&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_ display=2
  3. Lehmann BD, Bauer JA, Chen X, Sanders ME, et al. Iden- tifi ation of human triple-negative breast cancer subtypes and preclinical models for selection of targeted thera- J Clin Invest 2011; 121 (7): 2750–67. doi: 10.1172/ JCI45014.
  4. Hon JDC, Singh B, Sahin A, et Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res 2016; 6 (9): 1864–72.
  5. Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2015; 21 (7): 1688–98. doi: 1158/1078- 0432.CCR-14-0432.
  6. Jabbarzadeh Kaboli P, Shabani S, Sharma S, et al. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug c Am J Cancer Res 2022; 12 (4): 1671–85.
  1. Asano T. Drug resistance in cancer therapy and the role of epigenet J Nippon Med Sch Nippon Ika Daigaku Zasshi 2020; 87 (5): 244–51. doi: 10.1272/jnms.JNMS.2020_87- 508.
  2. Delgado JL, Hsieh CM, Chan NL, Hiasa Topoisomerases as anticancer targets. Biochem J 2018; 475 (2): 373–98. doi: 10.1042/BCJ20160583.
  3. Wang Interaction between DNA and an Escherichia coli protein omega. J Mol Biol 1971; 55 (3): 523–33.
  4. Gellert M, Mizuuchi K, O’Dea MH, Nash HA. DNA gy- rase: an enzyme that introduces superhelical turns into Proc Natl Acad Sci USA 1976; 73 (11): 3872–6. doi: 10.1016/0022-2836(71)90334-2.
  5. Tibau A, López-Vilaró L, Pérez-Olabarria M, et al. Chro- mosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. Neoplasia NYN 2014; 16 (10): 861–7. doi: 1016/j. neo.2014.08.012.
  6. Huang WC, Lee CY, Hsieh T. Single-molecule Förster reso- nance energy transfer (FRET) analysis discloses the dynam- ics of the DNA–topoisomerase II (Top2) interaction in the presence of TOP2-targeting J Biol Chem 2017; 292 (30): 12589–98. doi: 10.1074/jbc.M117.792861.
  7. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Trans- plant 2013; 48 (3): 452–8. doi: 1038/bmt.2012.244.
  8. Biostatics Analysis of the results of medical research in the EZR package (R-statistics) OA Lib [Internet]. [cited 2023 Apr 24]. Available from:

No comments » Add comment